Ionis Pharmaceuticals, Inc. (IONS) Return on equity 2016–2025
Ionis Pharmaceuticals, Inc. (IONS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-78.0%FY2025 · since FY2016: -60.7% → -78.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -78.0% | -0.8 pp |
| FY2024 | -77.1% | +17.6 pp |
| FY2023 | -94.7% | -47.6 pp |
| FY2022 | -47.1% | -43.4 pp |
| FY2021 | -3.7% | +56.1 pp |
| FY2020 | -59.8% | -78.7 pp |
| FY2019 | 18.9% | -7.2 pp |
| FY2018 | 26.1% | +26.0 pp |
| FY2017 | 0.1% | +60.8 pp |
| FY2016 | -60.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More IONS financial trends
IONS RevenueIONS Net incomeIONS Net marginIONS Gross profitIONS Gross marginIONS Operating incomeIONS Operating marginIONS Operating cash flowIONS Free cash flowIONS Capital expendituresIONS Stock buybacksIONS Dividends paidIONS Total assetsIONS Total liabilitiesIONS Shareholders’ equityIONS overview →